Which results from LEADER are the most transformative as far as CV risk reduction in T2D, and what might the implications be about the mechanism by which liraglutide reduces CV events?

Which results from LEADER are the most transformative as far as CV risk reduction in T2D, and what might the implications be about the mechanism by which liraglutide reduces CV events?

Which results from the LEADER trial do you consider to be most transformative as far as our approach to CV risk reduction in T2D, and what might the implications be about the mechanism by which liraglutide reduces CV events?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Steve Bain, MD

Steve Bain, MD

Professor of Medicine (Diabetes)
College of Medicine
Swansea University
Swansea, UK